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Abstract
Metabolic abnormalities are frequent in patients with 
schizophrenia and bipolar disorder (BD), leading to a high 
prevalence of diabetes and metabolic syndrome in this population. 
Moreover, mortality rates among patients are higher than in the 
general population, especially due to cardiovascular diseases. 
Several neurobiological systems involved in energy metabolism 
have been shown to be altered in both illnesses; however, 
the cause of metabolic abnormalities and how they relate to 
schizophrenia and BD pathophysiology are still largely unknown. 
The “selfish brain” theory is a recent paradigm postulating that, 
in order to maintain its own energy supply stable, the brain 
modulates energy metabolism in the periphery by regulation 
of both allocation and intake of nutrients. We hypothesize 
that the metabolic alterations observed in these disorders are 
a result of an inefficient regulation of the brain energy supply 
and its compensatory mechanisms. The selfish brain theory 
can also expand our understanding of stress adaptation and 
neuroprogression in schizophrenia and BD, and, overall, can 
have important clinical implications for both illnesses.
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metabolism, stress, allostasis.
 
Resumo
Alterações metabólicas são frequentes em pacientes com esqui-
zofrenia e transtorno bipolar (TB), levando a uma alta prevalên-
cia de diabetes e síndrome metabólica nessa população. Além 
disso, as taxas de mortalidade entre pacientes são mais altas 
do que na população geral, especialmente em decorrência de 
doenças cardiovasculares. Vários sistemas neurobiológicos en-
volvidos no metabolismo energético têm demonstrado alterações 
nas duas doenças; no entanto, a causa das alterações metabó-
licas e a forma como elas se relacionam com a fisiopatologia da 
esquizofrenia e do TB ainda são arenas em grande parte desco-
nhecidas. A teoria do “cérebro egoísta” é um paradigma recente 
que postula que, para manter estável seu próprio fornecimento 
de energia, o cérebro modula o metabolismo da energia na peri-
feria regulando tanto a alocação quanto a ingestão de nutrientes. 
Apresentamos neste artigo a hipótese de que as alterações me-
tabólicas observadas nesses transtornos são resultado de uma 
regulação ineficiente do fornecimento de energia do cérebro e 
seus mecanismos compensatórios. A teoria do cérebro egoísta 
também pode expandir nosso entendimento sobre a adaptação 
ao estresse e a neuroprogressão na esquizofrenia e no TB, e, 
acima de tudo, pode ter implicações clínicas importantes para 
as duas doenças.
Descritores: Esquizofrenia, transtorno bipolar, metabolismo, 
metabolismo cerebral, estresse, alostase.
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Introduction
Schizophrenia and bipolar disorder (BD) are frequent 
and potentially severe psychiatric disorders, which affect, 
together, 3% of the population.1,2 These illnesses typically 
start in adolescence or early adulthood and usually 
develop a chronic and debilitating course. According 
to the World Health Organization, both are among the 
10 major causes of disability.3 Despite progresses in 
treatment, medications are still limited in their clinical 
efficacy, and few individuals recover their previous level 
of functioning.4,5 Moreover, schizophrenia and BD are 
associated with a wide range of medical comorbidities,6,7 
with higher mortality rates than expected.8,9
Although schizophrenia and BD are distinct 
conditions, recent findings from several lines of 
evidence converge to the idea that they share several 
pathophysiological processes. There is a genetic 
susceptibility common to both of them, including the 
identification of genes, such as DISC1, dysbindin, 
NRG1-A, and DAO.10 Structural neuroimaging studies 
have also found similarities in the pattern of changes 
induced by the two diseases. For example, an increase 
of the lateral ventricles and a reduction in hippocampal 
volume have been found in both conditions, however 
more markedly in patients with schizophrenia than in 
those with BD.11 These volumetric deviations may be 
related to imbalances in factors regulating neuronal 
and glial survival. Reductions in neurotrophins, such as 
brain-derived neurotrophic factor (BDNF), have been 
repeatedly demonstrated in schizophrenia12 and BD 
both during mood episodes and in periods of euthymia.13 
Similarly, altered peripheral levels of mediators involved 
in the regulation of neuroplasticity, such as factors 
of apoptosis and inflammation markers, have been 
documented in schizophrenia14,15 and in BD.16-18
Recently, several authors have proposed that 
schizophrenia and BD are progressive in nature, with 
substantial differences between early and late stages in 
terms of clinical presentation, treatment response, and 
neurobiological characteristics.19,20 Shorter interepisodic 
intervals, worse cognitive functioning, increased risk 
of suicide, and a worse response to pharmacotherapy 
and psychotherapy are related with a greater number 
of episodes of BD.21 Late stages of these diseases 
are also associated with more pronounced brain 
morphology alterations, as well as other neurobiological 
abnormalities such as low levels of BDNF and increased 
levels of inflammatory cytokines and oxidative stress 
markers.22,23 However, despite the robust evidence 
pointing to the progressive nature of schizophrenia and 
BD, the neurobiological substrates of this progression 
are not well known.
Metabolic abnormalities in schizophrenia 
and BD
The increased mortality observed in patients 
with schizophrenia and BD, along with an increased 
incidence of cardiovascular disease and diabetes,24-26 
has motivated the investigation of metabolic alterations. 
In fact, the prevalence of obesity and metabolic 
syndrome is substantially higher in these patients than 
in the general population.27,28 Factors such as the use 
of medication, especially atypical antipsychotics, dietary 
habits, and lifestyle seem to exert an influence on this 
higher prevalence. However, studies involving first-
episode patients without previous use of medication 
have shown metabolic abnormalities to be present even 
before treatment.29-31 While a sedentary lifestyle and a 
poor diet are important factors, they alone are not able 
to explain all the differences observed.32 Results indicate 
that metabolic dysfunction is a component of the 
pathophysiology of disease from its onset. In addition, 
diabetes and metabolic syndrome are associated with 
brain changes similar to those of mental illness.33 Atrophy 
of structures such as the hippocampus and the amygdala 
have been reported,34,35 as well as cognitive deficits (e.g. 
worse performance on attention tasks, working memory, 
and executive function) that are indicative of brain 
dysfunction.36
Physiology of brain energy metabolism
The central nervous system (CNS) has some 
particularities in relation to energy metabolism. Brain 
tissue consumes high levels of energy; although the 
brain accounts for only 2% of the total body mass, it 
spends approximately 25% of the glucose available 
in the body. Neuronal activity and the release of 
neurotransmitters and neuropeptides require large 
amounts of energy.37 Despite this high demand, the CNS 
has a low storage capacity, with low levels of glycogen 
or lipids. Furthermore, brain tissue is almost entirely 
dependent on glucose metabolism, while peripheral 
tissues are able to use carbohydrates, proteins and fats. 
These characteristics make the maintenance of a steady 
supply of glucose crucial for a normal brain operation. 
The blood-brain barrier plays an important role in this 
regulation, since various substrates and hormones are 
actively transported by specific mechanisms.38
The “selfish brain” theory
Due to the special position of the CNS relative to 
energy metabolism, several authors have stated that this 
system actively regulates the production and distribution 
of energy throughout the body, with emphasis on 
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regulating its own adenosine triphosphate (ATP) 
concentration.39 This idea is supported by observations 
that, in situations of severe malnutrition, all organs, 
including the heart, lungs, and kidneys, show a decrease 
of up to 40% in weight, while brain tissue mass remains 
unchanged.40 Thus, some authors have developed the 
“selfish brain” theory,39 according to which the brain 
would prioritize its own availability of glucose.
The availability of energy to neurons is determined 
by the concentration of ATP. When ATP concentration 
decreases, an ATP-dependent potassium channel is 
opened, allowing the flow of potassium to the extracellular 
space, hyperpolarizing the neuron and making it refractory. 
Because there are differences in channel affinity between 
excitatory (glutamatergic – high affinity for ATP) and 
inhibitory (GABA – low affinity for ATP) neurons, low but 
non-critical levels of ATP reduce the activity of inhibitory 
neurons only, keeping excitatory ones active and thus 
leading to an increased release of glutamate in the 
system, with both local and systemic effects. Locally, 
glutamate release promotes glucose uptake by astrocytes 
through the blood-brain barrier, in order to balance the 
availability of ATP. Systemically, there is activation of the 
hypothalamic-pituitary-adrenal (HPA) axis and of the 
sympathetic nervous system (SNS), which together inhibit 
the absorption of glucose in the periphery, increasing 
its availability to the CNS and promoting an increase in 
appetite and food intake.39 
This theory was tested by Hitze et al.,41 who exposed 
individuals to a stressful situation and subsequently to a 
buffet with different types of food. Blood samples were 
collected throughout the study. Previous studies have 
shown that acute mental stress increases brain energy 
consumption by 12%.42 In the study by Hitze et al.,41 
exposure to stress increased the intake of carbohydrates, 
but not of fat and protein. Carbohydrate consumption, 
as expected, increased blood glucose, however with 
no subsequent increase in insulin among stressed 
individuals. Those findings suggest that stress response, 
through HPA axis activation, inhibited insulin secretion 
via the pancreas. As glucose uptake in the CNS is insulin-
independent, the suppression of the latter increases the 
amount of glucose available to the brain. This supports 
the concept that the brain modulates energy metabolism 
in the periphery in order to ensure an adequate energy 
supply and maintain normal functioning under different 
circumstances.
Metabolic systems involved in the patho-
physiology of psychiatric disorders 
Several neurobiological abnormalities related to energy 
metabolism, both centrally and peripherally, have been 
described in schizophrenia and BD. Astrocytes are glial 
cells responsible for glucose uptake from capillary vessels 
and, through the conversion and release of lactate, for 
the delivery of energetic substrate for neurons. Therefore, 
abnormalities in astrocytes may directly impact brain 
energy metabolism. Interestingly, astrocyte and glial cell 
pathology has been repeatedly shown in schizophrenia 
and BD, both in post-mortem and in neuroimaging 
studies.43,44 Moreover, the S100B protein can be found in 
glial cells, especially astrocytes, and has been considered 
as a marker of astrocyte integrity. Increased levels of 
this protein were found in schizophrenia, particularly in 
unmedicated patients,45,46 and also in BD patients, mainly 
during manic or depressive episodes.45,47
Because brain tissues use glucose metabolism as 
their energetic substrate, they are highly dependent on 
mitochondrial function. Any mitochondrial abnormality 
will greatly impact the brain. In patients with 
schizophrenia or BD, changes in the morphology and 
number of mitochondria have been detected in brain 
tissue,48,49 as well as a down-regulation of mitochondria-
related genes.50 Mitochondrial function, which involves 
ATP production, reactive oxygen species homeostasis, 
and apoptosis regulation, is also altered.51,52 Medications 
used in the treatment of these disorders have an influence 
on mitochondria, with mood stabilizers (e.g., lithium and 
valproate) reverting some of these abnormalities, which 
could explain the beneficial effects of these agents.53,54 
Curiously, antipsychotics may have the opposite effect 
and impair mitochondrial function.55,56
Peripherally, metabolic abnormalities are also observed. 
In addition to the higher prevalence of diabetes and insulin 
resistance mentioned above, first-episode, drug-naive 
patients already display increased levels of glucose and 
insulin, as well as insulin resistance rates.30,57,58 Insulin-
related peptides, such as proinsulin and peptide C, were 
also shown to be increased in this population, regardless 
of glucose levels.59 Alterations in the plasma levels of lipids 
are another common metabolic alteration of schizophrenia 
and BD. Triglyceri des and lipoproteins, such as low-density 
and high-density lipoproteins (LDL and HDL), have shown 
abnormal levels in chronic60,61 and first-episode, drug-
naive patients.62 Among fatty acids, the omega-3 group 
has been the focus of increasing attention, as a result 
of epidemiological studies linking high rates of dietary 
omega-3 with low levels of cardiovascular disease, diabetes, 
and depression.63 In fact, different levels of omega-3 have 
been reported in patients with schizophrenia and BD.64,65 
Interestingly, omega-3 fatty acids also have an important 
role in brain energy metabolism, exerting an influence on 
brain glucose uptake.66
The stress response system plays an important role in 
brain energy metabolism by increasing the availability of 
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energetic substrates and directing it to the CNS. It is also 
one of the most robust and most frequently replicated 
neurobiological abnormalities in schizophrenia and BD. 
Patients with schizophrenia present long periods of 
increased cortisol secretion, especially those experiencing 
their first episode and not previously treated.67 They 
also show low reactivity to stress, with a blunted 
cortisol response to psychosocial stress.67 In BD, studies 
have shown altered corticotropin-releasing hormone 
(CRH) secretion previous to symptom onset,68 cortisol 
hypersecretion in euthymia, depression and mania,69 
and a non-normalization of the HPA axis after symptom 
remission.70 Overall, evidence points to disturbances of 
the stress response system as a trait of both illnesses.
Another point of intersection between energy 
metabolism and psychiatric disorders is the BDNF. This 
protein is considered an important neuroplasticity marker 
and is involved in several processes, such as neuronal 
differentiation and synaptic plasticity.71 Altered BDNF 
levels and genetic expression are well documented in 
schizophrenia12 and BD,72,73 and are associated with 
episodes as well as with length of illness.12,13,73 Interestingly, 
BDNF has also been implicated in energy metabolism.74 
The Val66Met polymorphism of the BDNF gene is 
associated with a higher body mass index (BMI) in healthy 
individuals.75 In the hypothalamus, BDNF expression was 
shown to be inhibited by dietary restriction and enhanced 
by energy availability, especially glucose.76,77 Moreover, 
diminished BDNF expression produced hyperphagia and 
obesity in an animal model.77,78
Could all these metabolic abnormalities described in 
schizophrenia and BD be better explained by adopting 
a single and comprehensive paradigm? The selfish brain 
theory provides a cohesive conceptual framework for 
answering that question. We hypothesize that central 
and peripheral metabolic alterations are related to an 
inefficient regulation of brain energy homeostasis. A higher 
energetic demand, due to chronic exposure to stress, or a 
deregulation of cellular and hormonal metabolic processes 
could cause a deficit in brain energy supply, disrupting 
normal brain function and manifesting as psychopathology. 
Moreover, the adaptive mechanisms triggered by the effort 
of normalizing brain energy supply, such as HPA axis 
activation and food intake stimulation, might be the basis 
of the peripheral alterations often observed in the patients 
and that frequently develop into diabetes, metabolic 
syndrome, and cardiovascular disease.
Brain energy metabolism and stress adap-
tation
Stress represents a challenge to the system. In 
order to deal with this challenge, the mobilization of 
energetic resources is necessary. As discussed above, 
stressful experiences can increase the brain metabolic 
activity by 12%.42 In fact, even cognitive work, as in 
computer-based activities or video game playing, 
appears to increase brain demand and consequently 
food intake.79 Hypoglycemic states are known to induce 
neuroglycopenic symptoms, such as hunger, dizziness, 
and difficulty thinking.80 Stressed individuals, however, 
show these neuroglycopenic symptoms even at normal 
blood glucose level, corresponding to a state of 
energetic deficit in the brain.41 Interestingly, individuals 
have also been reported to develop mood symptoms 
after a stressful experience, and these were, as were 
neuroglycopenic symptoms, reversed after energy 
supplementation.41 Energy deficit disrupts normal brain 
functions; therefore, brain homeostasis is directly linked 
to the system’s capacity of achieving energetic balance.
Adaptation to stress is now recognized as an important 
factor in the pathophysiology of both schizophrenia and 
BD.81 In addition, stressful events are common triggers 
of psychotic and mood episodes.82,83 Several known risk 
factors for both illnesses, such as early life adversities, 
childhood maltreatment, urbanicity, and drug abuse, 
directly impact and modulate stress response systems, 
and the risk of developing schizophrenia or BD is known 
to increase with a cumulative exposure to stressful life 
events.84 The impact of stress seems to be stronger in 
the period preceding the onset of the first episode,85-87 
although it is also associated with symptom severity 
and chronicity.88 Moreover, patients exhibit a higher 
sensitivity to daily life stress, which has important 
clinical implications.89
Despite the irrefutable evidence of the major role of 
stress in schizophrenia and BD, it remains unclear how 
and through which mechanisms this pathophysiological 
process occurs. The relationship between stress and 
psychopathology is not merely linear. Health is not just 
a static point of equilibrium; it also involves the capacity 
to adapt to the environment and meet external and 
internal demands.90 Allostasis is a more recent model 
of regulation and is focused on anticipatory responses 
to predicted demands.90,91 This model highlights the 
importance of brain control over regulatory processes, 
allowing stability points to fluctuate according to 
environmental demands.90,91 Allostasis also involves 
an intricate and orchestrated network of mediators92 
that enhance regulation efficiency through broad and 
complementary responses.90 For example, hypoglycemia 
stimulates the secretion of several hormones, such as 
glucagon and growth hormone, activates the autonomic 
nervous system, and, most importantly, provokes 
the sensation of hunger and motivates food seeking 
behavior. The allostasis model provides a better and more 
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comprehensive paradigm for the study of stress in the 
pathophysiology of schizophrenia and BD. Brain energy 
metabolism regulation, as described by the selfish brain 
theory, is intrinsically related to stress adaptation and can 
serve as a new theoretical framework integrating stress 
response abnormalities and the metabolic alterations 
observed in patients with schizophrenia and BD.
Clinical implications of brain energy me-
tabolism dysfunction
Schizophrenia and BD are progressive disorders.19,20 
Several clinical features, such as severity and persistence 
of symptoms, cognitive and functional impairment, 
suicide risk, as well as treatment response, are clearly 
associated with length of illness and/or number of 
episodes.93 Clinical progression is accompanied by 
neuroprogression, as shown by evidence pertaining to 
biomarkers and neuroanatomical differences between 
early and late illness stages.22 Putatively, neuroprogression 
is caused by the accumulation of stress exposure and its 
adaptive responses over time, a process that is called 
allostatic load.94 Several biomarkers have been proposed 
as mediators of allostatic load, e.g., inflammatory and 
oxidative stress markers.94 Regulatory mechanisms of 
brain energy play a major role in adaptive and allostatic 
processes. Dysfunction of these mechanisms may be a 
contributing factor to neuroprogression in schizophrenia 
and BD.
Cognitive impairment is a core feature of 
schizophrenia and BD, being highly prevalent and one of 
the most important causes of disability.95,96 It is also one 
of the consequences of the progressive nature of these 
illnesses.93 As seen above, cognitive work is energetically 
demanding79; consequentially, based on our hypothesis, 
it can be disturbed by an inefficient regulation of 
brain energy. This highlights the importance of taking 
metabolic issues into account in studies focusing on 
cognition. Moreover, interventions focused on brain 
energy dysfunction, such as pharmacological approaches 
or dietary and lifestyle changes, may be beneficial for 
cognitive function.
 Finally, another clinical implication of recognizing 
brain energy dysfunction as a component of the 
pathophysiology of schizophrenia and BD is related 
to prevention. From the concept of neuroprogression 
arises the idea that early intervention may prevent a 
deteriorative course of illness.23 In fact, there is currently 
a major ongoing effort in psychiatric research to optimize 
early recognition and diagnosis of schizophrenia and 
BD, including the identification of prodromal states.97,98 
Studies focusing on pre-clinical stages, the so-called “at-
risk mental states,” are successfully developing criteria to 
reliably identify those individuals.97 Intervention studies 
have also been conducted in an attempt to prevent the 
development of a full-blown, clinical illness.99 However, 
due to the complex and dynamic nature of schizophrenia 
and BD, identification criteria are not totally accurate 
and tend to have a high rate of false positive results.97 
This raises a major concern on the use of psychotropic 
medications in this population.100 Rather, interventions 
focused on brain energy regulation may be capable of a 
disease-modifier effect, without the risk and side effects 
associated with medications.
Conclusion
Metabolic abnormalities are common in schizophrenia 
and BD, involving a plethora of neurobiological systems 
related to energy regulation. The selfish brain theory 
postulates that the CNS modulates energy metabolism 
in the periphery in order to prioritize its own demand,39 
providing a unified conceptual framework for the 
understanding of these phenomena. Brain energy 
regulation is also a crucial component of stress adaptation, 
in both short and long terms. An inefficient regulation 
can be associated with pathological processes in the 
body and in the brain. Therefore, a better understating 
of how this regulation takes place in schizophrenia and 
BD patients could help elucidate several features of 
these illnesses and provide a platform for further studies 
of pathophysiology and intervention.
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